Literature DB >> 27558969

Impact of holoprosencephaly, exomphalos, megacystis and increased nuchal translucency on first-trimester screening for chromosomal abnormalities.

A Syngelaki1, L Guerra1, I Ceccacci1, T Efeturk1, K H Nicolaides1.   

Abstract

OBJECTIVES: To examine the prevalence of alobar holoprosencephaly, exomphalos, megacystis and nuchal translucency thickness (NT) ≥ 3.5 mm, the incidence and types of chromosomal abnormalities associated with these conditions and their overall impact on the rate of invasive testing and performance of screening at 11-14 weeks.
METHODS: This was a prospective screening study for trisomies 21, 18 and 13 by the first-trimester combined test at three maternity units in England.
RESULTS: In the study population of 108 982 singleton pregnancies, 870 (0.8%) had abnormal karyotype, including 654 (75.2%) with trisomies 21, 18 or 13 and 216 (24.8%) with other chromosomal abnormalities. The prevalence of alobar holoprosencephaly, exomphalos, megacystis and NT ≥ 3.5 mm was 1 in 2945, 1 in 419, 1 in 1345 and 1 in 119, respectively. Chromosomal abnormalities were observed in 78.4% of cases of holoprosencephaly, 40.8% of exomphalos, 18.5% of megacystis and 48.5% of those with NT ≥ 3.5 mm. The most common chromosomal abnormality associated with holoprosencephaly was trisomy 13, with exomphalos and megacystis was trisomy 18 and with increased NT was trisomy 21. Fetal karyotyping of cases with major fetal defects or increased NT would potentially detect 57% of all chromosomal abnormalities at an invasive testing rate of 1.1%.
CONCLUSION: Major fetal defects and increased NT at 11-13 weeks' gestation are associated with a high risk of chromosomal abnormalities and merit invasive fetal testing.
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  chromosomal abnormalities; exomphalos; first-trimester screening; holoprosencephaly; megacystis; nuchal translucency

Mesh:

Year:  2017        PMID: 27558969     DOI: 10.1002/uog.17286

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  7 in total

1.  How to perform a sonographic morphological assessment of the fetus at 11-14 weeks of gestation.

Authors:  Edward Andrew Springhall; Daniel Lorber Rolnik; Maya Reddy; Sujatha Ganesan; Maria Maxfield; Jayshree Ramkrishna; Simon Meagher; Mark Teoh; Fabricio da Silva Costa
Journal:  Australas J Ultrasound Med       Date:  2018-08-22

2.  Antenatal Workup of Early Megacystis and Selection of Candidates for Fetal Therapy.

Authors:  Federica Fontanella; Leonie Duin; Phebe N Adama van Scheltema; Titia E Cohen-Overbeek; Eva Pajkrt; Mireille Bekker; Christine Willekes; Caroline J Bax; Dick Oepkes; Catia M Bilardo
Journal:  Fetal Diagn Ther       Date:  2018-05-17       Impact factor: 2.587

3.  Prenatal diagnosis of exomphalos and prediction of outcome.

Authors:  K Nitzsche; G Fitze; M Rüdiger; P Wimberger; C Birdir
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

4.  Different Cutoff Values for Increased Nuchal Translucency in First-Trimester Screening to Predict Fetal Chromosomal Abnormalities.

Authors:  Linjuan Su; Xiaoqing Wu; Na Lin; Xiaorui Xie; Meiying Cai; Meiying Wang; Lin Zheng; Liangpu Xu
Journal:  Int J Gen Med       Date:  2021-11-18

5.  Vesicoamniotic Shunting before 17 + 0 Weeks in Fetuses with Lower Urinary Tract Obstruction (LUTO): Comparison of Somatex vs. Harrison Shunt Systems.

Authors:  Brigitte Strizek; Theresa Spicher; Ingo Gottschalk; Paul Böckenhoff; Corinna Simonini; Christoph Berg; Ulrich Gembruch; Annegret Geipel
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.241

6.  Chromosomal microarray analysis versus noninvasive prenatal testing in fetuses with increased nuchal translucency.

Authors:  Chaohong Wang; Junxiang Tang; Keting Tong; Daoqi Huang; Huayu Tu; Jiansheng Zhu
Journal:  J Hum Genet       Date:  2022-05-17       Impact factor: 3.755

Review 7.  Antenatal screening for chromosomal abnormalities.

Authors:  Karl Oliver Kagan; Jiri Sonek; Peter Kozlowski
Journal:  Arch Gynecol Obstet       Date:  2022-03-13       Impact factor: 2.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.